CAMBRIDGE & WETHERBY, England--(BUSINESS WIRE)--Avacta Group plc (AIM: AVCT), the developer of diagnostics and innovative cancer therapies based on its proprietary Affimer® and pre|CISION™ platforms, ...
Add Yahoo as a preferred source to see more of our stories on Google. As a result of the rapidly-spreading Omicron variant, Covid case numbers have continued to rise across the UK in record numbers, ...
In our best practices blog, we explore how lateral flow assay design affects test performance. Read on to gain a deeper understanding of the development process, enabling you to streamline the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results